These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18593345)

  • 41. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 42. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Indinavir (Crixivan).
    Res Initiat Treat Action; 2000 Mar; 6(1):28-9. PubMed ID: 11708184
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy.
    Koch N; Yahi N; Ariasi F; Fantini J; Tamalet C
    J Clin Microbiol; 1999 May; 37(5):1595-7. PubMed ID: 10203532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection.
    Ma J; Chen Z; Fu C; Wei S; Liu J; Yang X; Chen X; Zhao Q; Sun Y; Huo Y
    Front Cell Infect Microbiol; 2023; 13():1249837. PubMed ID: 38179423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting HIV drug resistance with neural networks.
    Drăghici S; Potter RB
    Bioinformatics; 2003 Jan; 19(1):98-107. PubMed ID: 12499299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments.
    Arias A; López P; Sánchez R; Yamamura Y; Rivera-Amill V
    Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30096879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid deep sequencing of patient-derived HIV with ion semiconductor technology.
    Chang MW; Oliveira G; Yuan J; Okulicz JF; Levy S; Torbett BE
    J Virol Methods; 2013 Apr; 189(1):232-4. PubMed ID: 23384677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterizing the relationship between HIV-1 genotype and phenotype: prediction-based classification.
    Foulkes AS; De GV
    Biometrics; 2002 Mar; 58(1):145-56. PubMed ID: 11890310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of drug resistance mutations in HIV from constraints on natural evolution.
    Butler TC; Barton JP; Kardar M; Chakraborty AK
    Phys Rev E; 2016 Feb; 93(2):022412. PubMed ID: 26986367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Development of microchips for the detection of mutations of HIV-1 variability to protease inhibitors and the usage results].
    Rudinskiĭ NI; Mikhaĭlovich VM; Donnikov MIu; Lapa SA; Sukhanova AL; Kazennova EV; Bobkov AF; Zasedatelev AS; Pokrovskiĭ VV; Mirzabekov AD
    Vopr Virusol; 2004; 49(6):10-5. PubMed ID: 15597954
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New resistance score for tipranavir.
    Poveda E
    AIDS Rev; 2008; 10(2):127. PubMed ID: 18615125
    [No Abstract]   [Full Text] [Related]  

  • 55. Oropharyngeal candidiasis in HIV(+) patients may influence the selection of HIV-1 protease variants.
    Hickman PJ; Leigh JE; Mera RM; Fidel PL; Luftig RB
    Virus Res; 2002 Aug; 87(2):97-106. PubMed ID: 12191773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro.
    Lü JM; Yan S; Jamaluddin S; Weakley SM; Liang Z; Siwak EB; Yao Q; Chen C
    Med Sci Monit; 2012 Aug; 18(8):BR293-298. PubMed ID: 22847190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MrHAMER yields highly accurate single molecule viral sequences enabling analysis of intra-host evolution.
    Gallardo CM; Wang S; Montiel-Garcia DJ; Little SJ; Smith DM; Routh AL; Torbett BE
    Nucleic Acids Res; 2021 Jul; 49(12):e70. PubMed ID: 33849057
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disregarding drug resistance mutations without peril.
    Richman DD
    AIDS; 2021 Jun; 35(7):1135-1136. PubMed ID: 33946088
    [No Abstract]   [Full Text] [Related]  

  • 59. HIV-1 DNA Testing in Viremic Patients Identifies More Drug Resistance Than HIV-1 RNA Testing.
    Curanovic D; Martens SK; Rodriguez MA; Hammill HA; Petropoulos CJ; Walworth CM
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad146. PubMed ID: 37065991
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiretroviral Drug-Resistance Mutations on the
    Hunter JR; Dos Santos DEM; Munerato P; Janini LM; Castelo A; Sucupira MC; Truong HM; Diaz RS
    Pathogens; 2022 May; 11(5):. PubMed ID: 35631055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.